Additive IOP - reducing effect of latanoprost in <font color="red">patients_2</font> <font color="red">insufficiently_2</font> <font color="red">controlled_2</font> <font color="red">on_2</font> <font color="red">timolol_2</font> <font color="red">._1</font> 
<br>
<br> PURPOSE To evaluate the effect on intraocular pressure ( IOP ) of switching from timolol to latanoprost or adding latanoprost to timolol <font color="red">in_1</font> <font color="red">patients_2</font> <font color="red">with_2</font> <font color="red">open_2</font> <font color="red">angle_2</font> <font color="red">glaucoma_2</font> <font color="red">or_2</font> <font color="red">ocular_2</font> <font color="red">hypertension_2</font> <font color="red">where_2</font> <font color="red">IOP_2</font> <font color="red">is_2</font> <font color="red">not_2</font> <font color="red">adequately_2</font> <font color="red">controlled_2</font> <font color="red">with_2</font> <font color="red">timolol_2</font> <font color="red">._2</font> 
<br> METHODS This was a 6-week , double - masked , randomised multi - centre study . <font color="red">53_6</font> <font color="red">patients_6</font> <font color="red">with_6</font> <font color="red">primary_6</font> <font color="red">open_6</font> <font color="red">angle_6</font> <font color="red">glaucoma_6</font> <font color="red">,_6</font> <font color="red">capsular_5</font> <font color="red">glaucoma_5</font> <font color="red">,_5</font> <font color="red">or_4</font> <font color="red">ocular_4</font> <font color="red">hypertension_4</font> <font color="red">with_4</font> <font color="red">an_4</font> <font color="red">IOP_4</font> <font color="red">of_4</font> <font color="red">at_4</font> <font color="red">least_4</font> <font color="red">21_4</font> <font color="red">mmHg_4</font> <font color="red">on_4</font> <font color="red">current_4</font> <font color="red">therapy_4</font> <font color="red">were_1</font> <font color="red">recruited_1</font> <font color="red">._1</font> After a run - in period of at least 2 weeks on timolol , 5 mg / ml twice daily , patients were randomised to <font color="red">one_1</font> <font color="red">of_1</font> <font color="red">three_1</font> <font color="red">groups_1</font> <font color="red">._1</font> <font color="red">One_1</font> <font color="red">group_1</font> continued on timolol , one switched from timolol to latanoprost , 50 microg / ml once daily , and a <font color="red">third_1</font> <font color="red">group_1</font> received latanoprost in addition to timolol . The efficacy was evaluated by comparing IOP at 9 AM at baseline and after 6 weeks of treatment . 
<br> RESULTS IOP at baseline and after 6 weeks of treatment ( mean + /- SEM ) were 24.2 + /- 0.9 and 23.8 + /- 1.0 mmHg ( n = 16 ) for patients continuing on timolol , 26.3 + /- 1.2 and 19.6 + /- 1.1 mmHg ( n = 17 ) for <font color="red">patients_1</font> switching to latanoprost , and 23.2 + /- 1.0 and 17.5 + /- 0.8 mmHg ( n = 17 ) for patients with combined treatment . Adding latanoprost to timolol reduced IOP with 5.9 + /- 0.9 mmHg ( p < 0.001 ) and switching from timolol to latanoprost reduced IOP with 5.0 + /- 0.9 mmHg ( p < 0.001 ) , which caused in each group a significant IOP reduction of about 25% . 
<br> CONCLUSIONS The effect of latanoprost was additive to that of timolol , and a good effect on IOP reduction was also achieved by switching from timolol to latanoprost , suggesting that a switch in many patients is an effective alternative to combination treatment .